Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. 2003

Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
Department of Internal Medicine I, San Raffaele Scientific Institute, Milan, Italy.

OBJECTIVE Our aim was to evaluate the long-term effects of transplanted islets on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. METHODS A total of 34 type 1 diabetic kidney-transplanted patients underwent islet transplantation and were divided into two groups: successful islet-kidney transplantation (SI-K; 21 patients, fasting C-peptide serum concentration >0.5 ng/ml for >1 year) and unsuccessful islet-kidney transplantation (UI-K; 13 patients, fasting C-peptide serum concentration <0.5 ng/ml). Patients cumulative survival, cardiovascular death rate, and atherosclerosis progression were compared in the two groups. Skin biopsies, endothelial dependent dilation (EDD), nitric oxide (NO) levels, and atherothrombotic risk factors [von Willebrand factor (vWF) and D-dimer fragment (DDF)] were studied cross-sectionally. RESULTS The SI-K group showed a significant better patient survival rate (SI-K 100, 100, and 90% vs. UI-K 84, 74, and 51% at 1, 4, and 7 years, respectively, P = 0.04), lower cardiovascular death rate (SI-K 1/21 vs. UI-K 4/13, chi(2) = 3.9, P = 0.04), and lower intima-media thickness progression than the UI-K group (SI-K group: delta1-3 years -13 +/- 30 micro m vs. UI-K group: delta1-3 years 245 +/- 20 micro m, P = 0.03) with decreased signs of endothelial injuring at skin biopsy. Furthermore, the SI-K group showed a higher EDD than the UI-K group (EDD: SI-K 7.8 +/- 4.5% vs. UI-K 0.5 +/- 2.7%, P = 0.02), higher basal NO (SI-K 42.9 +/- 6.5 vs. UI-K 20.2 +/- 6.8 micro mol/l, P = 0.02), and lower levels of vWF (SI-K 138.6 +/- 15.3 vs. UI-K 180.6 +/- 7.0%, P = 0.02) and DDF (SI-K 0.61 +/- 0.22 vs. UI-K 3.07 +/- 0.68 micro g/ml, P < 0.01). C-peptide-to-creatinine ratio correlated positively with EDD and NO and negatively with vWF and DDF. CONCLUSIONS Successful islet transplantation improves survival, cardiovascular, and endothelial function in type 1 diabetic kidney-transplanted patients.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D003925 Diabetic Angiopathies VASCULAR DISEASES that are associated with DIABETES MELLITUS. Diabetic Vascular Complications,Diabetic Vascular Diseases,Microangiopathy, Diabetic,Angiopathies, Diabetic,Angiopathy, Diabetic,Diabetic Angiopathy,Diabetic Microangiopathies,Diabetic Microangiopathy,Diabetic Vascular Complication,Diabetic Vascular Disease,Microangiopathies, Diabetic,Vascular Complication, Diabetic,Vascular Complications, Diabetic,Vascular Disease, Diabetic,Vascular Diseases, Diabetic
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
July 2001, Kidney international,
Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
October 2011, Transplantation proceedings,
Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
April 2004, Transplantation proceedings,
Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
August 1991, Diabetologia,
Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
June 2005, Nihon rinsho. Japanese journal of clinical medicine,
Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
February 2002, Transplantation proceedings,
Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
January 2020, Cell transplantation,
Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
January 1989, Transplantation,
Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
April 2016, Diabetologia,
Paolo Fiorina, and Franco Folli, and Federico Bertuzzi, and Paola Maffi, and Giovanna Finzi, and Massimo Venturini, and Carlo Socci, and Alberto Davalli, and Elena Orsenigo, and Lucilla Monti, and Luca Falqui, and Silvia Uccella, and Stefano La Rosa, and Luciana Usellini, and Giuliana Properzi, and Valerio Di Carlo, and Alessandro Del Maschio, and Carlo Capella, and Antonio Secchi
August 1984, Lancet (London, England),
Copied contents to your clipboard!